Literature DB >> 29958221

Potent Inactivation-Dependent Inhibition of Adult and Neonatal NaV1.5 Channels by Lidocaine and Levobupivacaine.

Taha Elajnaf1, Daniel T Baptista-Hon, Tim G Hales.   

Abstract

BACKGROUND: Cardiotoxic effects of local anesthetics (LAs) involve inhibition of NaV1.5 voltage-gated Na channels. Metastatic breast and colon cancer cells also express NaV1.5, predominantly the neonatal splice variant (nNaV1.5) and their inhibition by LAs reduces invasion and migration. It may be advantageous to target cancer cells while sparing cardiac function through selective blockade of nNaV1.5 and/or by preferentially affecting inactivated NaV1.5, which predominate in cancer cells. We tested the hypotheses that lidocaine and levobupivacaine differentially affect (1) adult (aNaV1.5) and nNaV1.5 and (2) the resting and inactivated states of NaV1.5.
METHODS: The whole-cell voltage-clamp technique was used to evaluate the actions of lidocaine and levobupivacaine on recombinant NaV1.5 channels expressed in HEK-293 cells. Cells were transiently transfected with cDNAs encoding either aNaV1.5 or nNaV1.5. Voltage protocols were applied to determine depolarizing potentials that either activated or inactivated 50% of maximum conductance (V½ activation and V½ inactivation, respectively).
RESULTS: Lidocaine and levobupivacaine potently inhibited aNaV1.5 (IC50 mean [SD]: 20 [22] and 1 [0.6] μM, respectively) and nNaV1.5 (IC50 mean [SD]: 17 [10] and 3 [1.6] μM, respectively) at a holding potential of -80 mV. IC50s differed significantly between lidocaine and levobupivacaine with no influence of splice variant. Levobupivacaine induced a statistically significant depolarizing shift in the V½ activation for aNaV1.5 (mean [SD] from -32 [4.6] mV to -26 [8.1] mV) but had no effect on the voltage dependence of activation of nNaV1.5. Lidocaine had no effect on V½ activation of either variant but caused a significantly greater depression of maximum current mediated by nNaV1.5 compared to aNaV1.5. Similar statistically significant shifts in the V½ inactivation (approximately -10 mV) occurred for both LAs and NaV1.5 variants. Levobupivacaine (1 μM) caused a significantly greater slowing of recovery from inactivation of both variants than did lidocaine (10 μM). Both LAs caused approximately 50% tonic inhibition of aNaV1.5 or nNaV1.5 when holding at -80 mV. Neither LA caused tonic block at a holding potential of either -90 or -120 mV, voltages at which there was little steady-state inactivation. Higher concentrations of either lidocaine (300 μM) or levobupivacaine (100 μM) caused significantly more tonic block at -120 mV.
CONCLUSIONS: These data demonstrate that low concentrations of the LAs exhibit inactivation-dependent block of NaV1.5, which may provide a rationale for their use to safely inhibit migration and invasion by metastatic cancer cells without cardiotoxicity.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29958221     DOI: 10.1213/ANE.0000000000003597

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  7 in total

1.  Inhibitory Effect of Eslicarbazepine Acetate and S-Licarbazepine on Nav1.5 Channels.

Authors:  Theresa K Leslie; Lotte Brückner; Sangeeta Chawla; William J Brackenbury
Journal:  Front Pharmacol       Date:  2020-10-02       Impact factor: 5.810

2.  Chronic neural activity recorded within breast tumors.

Authors:  Grant A McCallum; Jay Shiralkar; Diana Suciu; Gil Covarrubias; Jennifer S Yu; Efstathios Karathanasis; Dominique M Durand
Journal:  Sci Rep       Date:  2020-09-09       Impact factor: 4.379

3.  Lidocaine inhibits the metastatic potential of ovarian cancer by blocking NaV 1.5-mediated EMT and FAK/Paxillin signaling pathway.

Authors:  Chang Liu; Ming Yu; Yi Li; Hao Wang; Chuanya Xu; Xiaoqing Zhang; Min Li; Hongyan Guo; Daqing Ma; Xiangyang Guo
Journal:  Cancer Med       Date:  2020-12-06       Impact factor: 4.452

Review 4.  Pharmacological and nutritional targeting of voltage-gated sodium channels in the treatment of cancers.

Authors:  Osbaldo Lopez-Charcas; Piyasuda Pukkanasut; Sadanandan E Velu; William J Brackenbury; Tim G Hales; Pierre Besson; Juan Carlos Gomora; Sébastien Roger
Journal:  iScience       Date:  2021-03-06

Review 5.  A novel definition and treatment of hyperinflammation in COVID-19 based on purinergic signalling.

Authors:  Djo Hasan; Atsuko Shono; Coenraad K van Kalken; Peter J van der Spek; Eric P Krenning; Toru Kotani
Journal:  Purinergic Signal       Date:  2021-11-10       Impact factor: 3.765

Review 6.  Application of Anesthetics in Cancer Patients: Reviewing Current Existing Link With Tumor Recurrence.

Authors:  Xiaotian Liu; Qian Wang
Journal:  Front Oncol       Date:  2022-02-28       Impact factor: 6.244

7.  The influence of TIVA or inhalation anesthesia with or without intravenous lidocaine on postoperative outcome in colorectal cancer surgery: a study protocol for a prospective clinical study.

Authors:  Alexandru L Alexa; Tiberiu F Tat; Daniela Ionescu
Journal:  Trials       Date:  2022-03-18       Impact factor: 2.279

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.